Lynda Haver, DPM
Podiatrist · Indianola, IANPI 1831275767
Payments from drug & device makers
What this record shows
Treace Medical Concepts, Inc. accounts for 65.3% of it on its own, with 7 other manufacturers making up the rest. 2023 is the largest year on record at $1,633, 2.4 times the $691 reported in 2019.
Across 13 payments — averaging $192.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Treace Medical Concepts, Inc.$2K
- Smith+Nephew$292
- Musculoskeletal Transplant Foundation Inc.$127
- Osiris Therapeutics Inc.$122
- Organogenesis Inc.$116
- Johnson & Johnson$103
- plus $107 from 2 others
What the payments were for
- Travel & lodging$1,22949%
- Food & beverage$1,27151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Treace Medical Concepts, Inc. | 4 | $1,633 |
| Smith+Nephew | 3 | $292 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $127 |
| Osiris Therapeutics Inc. | 1 | $122 |
| Organogenesis Inc. | 1 | $116 |
| Johnson & Johnson | 1 | $103 |
| Actelion Pharmaceuticals US, Inc. | 1 | $57 |
| Tactile Systems Technology Inc | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lapiplasty System$1,633
- Stravix$242
- Santyl$125
- REGRANEX$125
- Oasis$125
- Grafix$122
- GrafixPL$122
- Grafix PL PRIME$121
- Apligraf$116
- XARELTO$103
How this compares
$2,501 in reported general payments places this provider in the 60th percentile of 94 podiatrist providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 13 | $639 |
| Clotrimazole | 20 | $433 |
| Gabapentin | 11 | $232 |
| Mupirocin | 12 | $137 |
| Cephalexin | 18 | $117 |
| Meloxicam | 13 | $12 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Indianola
- Paul DaytonAnkeny$9.4M
- Mindi DaytonAnkeny$333K
- Eric BarpWest Des Moines$149K
- Travis TidwellWaterloo$33K
- Eric TempleWest Des Moines$19K
- Eric JensenCarroll$17K
- Eric ReeseWest Des Moines$14K
- Andrew StanislavCouncil Bluffs$13K
- Jeffrey KileyCouncil Bluffs$12K
- Ronald KaneWaterloo$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.